- Home
- JMSB vs AVIR Comparison
JMSB vs AVIR Comparison
Compare JMSB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | AVIR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 318.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JMSB | AVIR |
|---|---|---|
| Price | $20.10 | $4.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $6.00 |
| AVG Volume (30 Days) | 19.9K | ★ 599.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.30 | N/A |
| Revenue Next Year | $9.72 | N/A |
| P/E Ratio | $13.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.81 | $2.46 |
| 52 Week High | $21.58 | $4.63 |
Technical Indicators
Market Signals| Indicator | JMSB | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 69.10 |
| Support Level | $19.89 | $4.04 |
| Resistance Level | $21.20 | $4.50 |
| Average True Range (ATR) | 0.45 | 0.25 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 29.39 | 96.55 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).